Source: http://www.google.com/patents/US8119608?dq=patent:5881444
Timestamp: 2016-07-26 03:30:23
Document Index: 358405201

Matched Legal Cases: ['art 1', 'Application No. 2009', 'Application No. 2009', 'Application No. 2009', 'Application No. 2009', 'Application No. 10066344', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007', 'Application No. 32713', 'Application No. 778474', 'Application No. 2005201044', 'Application No. 2005201044', 'art 1']

Patent US8119608 - Method and medicament for inhibiting the expression of a given gene - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention provides methods and compositions for inhibiting gene expression using double stranded RNA molecules that are between 15 and 24 nucleotides in length and are complementary to a target gene sequence....http://www.google.com/patents/US8119608?utm_source=gb-gplus-sharePatent US8119608 - Method and medicament for inhibiting the expression of a given geneAdvanced Patent SearchPublication numberUS8119608 B2Publication typeGrantApplication numberUS 10/383,099Publication dateFeb 21, 2012Filing dateMar 6, 2003Priority dateJan 30, 1999Fee statusPaidAlso published asCA2359180A1, CA2359180C, DE10066235B4, DE10066235C5, DE10080167B4, DE10080167D2, DE19956568A1, DE20023125U1, DE20023125U8, DE50000414D1, DE50010528D1, DE50015501D1, EP1144623A1, EP1144623B1, EP1144623B9, EP1214945A2, EP1214945A3, EP1214945B1, EP1550719A1, EP1550719B1, EP1798285A1, EP2363479A1, EP2363479B1, EP3018207A1, US8101584, US8101742, US8114851, US8114981, US8168776, US8183362, US8202980, US8729037, US8877726, US9133454, US20040053875, US20040072779, US20040102408, US20050100907, US20080166800, US20080171861, US20080171862, US20080182981, US20080233651, US20080261303, US20130164366, US20130164843, US20130177631, US20140051166, US20140220113, US20140220676, WO2000044895A1Publication number10383099, 383099, US 8119608 B2, US 8119608B2, US-B2-8119608, US8119608 B2, US8119608B2InventorsRoland Kreutzer, Stefan LimmerOriginal AssigneeAlnylam Pharmaceuticals, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (149), Non-Patent Citations (530), Referenced by (3), Classifications (26), Legal Events (6) External Links: USPTO, USPTO Assignment, EspacenetMethod and medicament for inhibiting the expression of a given gene
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4868116Jul 9, 1986Sep 19, 1989Whitehead Institute For Biomedical ResearchIntroduction and expression of foreign genetic material in epithelial cellsUS4980286Jan 3, 1989Dec 25, 1990Whitehead Institute For Biomedical ResearchIn vivo introduction and expression of foreign genetic material in epithelial cellsUS4987071Dec 3, 1986Jan 22, 1991University Patents, Inc.RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methodsUS5107065Aug 30, 1988Apr 21, 1992Calgene, Inc.Anti-sense regulation of gene expression in plant cellsUS5112734May 26, 1989May 12, 1992Gene-Trak SystemsTarget-dependent synthesis of an artificial gene for the synthesis of a replicatable rnaUS5190931Nov 15, 1989Mar 2, 1993The Research Foundation Of State University Of New YorkRegulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNAUS5208149Apr 10, 1992May 4, 1993The Research Foundation Of State University Of New YorkNucleic acid constructs containing stable stem and loop structuresUS5212295Oct 15, 1991May 18, 1993Isis PharmaceuticalsMonomers for preparation of oligonucleotides having chiral phosphorus linkagesUS5225347Mar 19, 1990Jul 6, 1993Innovir Laboratories, Inc.Therapeutic ribozyme compositions and expression vectorsUS5246921Aug 5, 1992Sep 21, 1993The Wistar Institute Of Anatomy And BiologyMethod for treating leukemiasUS5254678Aug 5, 1992Oct 19, 1993Gene Shears Pty. LimitedRibozymesUS5328470Jul 26, 1991Jul 12, 1994The Regents Of The University Of MichiganTreatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits thereforUS5496698Dec 7, 1992Mar 5, 1996Ribozyme Pharmaceuticals, Inc.Method of isolating ribozyme targetsUS5525468Aug 1, 1994Jun 11, 1996Ribozyme Pharmaceuticals, Inc.Assay for Ribozyme target siteUS5574142Dec 15, 1992Nov 12, 1996Microprobe CorporationPeptide linkers for improved oligonucleotide deliveryUS5587361Jun 6, 1995Dec 24, 1996Isis Pharmaceuticals, Inc.Oligonucleotides having phosphorothioate linkages of high chiral purityUS5616459Aug 18, 1992Apr 1, 1997The Public Health Research Institute Of The City Of New York, Inc.Selection of ribozymes that efficiently cleave target RNAUS5624803Oct 13, 1994Apr 29, 1997The Regents Of The University Of CaliforniaIn vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefromUS5635385Sep 15, 1993Jun 3, 1997Temple University-Of The Commonwealth System Of Higher EducationMulti-unit ribozyme inhibition of oncogene gene expressionUS5639655Apr 25, 1994Jun 17, 1997Ribozyme Pharmaceuticals, Inc.PML-RARA targeted ribozymesUS5674683Mar 21, 1995Oct 7, 1997Research Corporation Technologies, Inc.Stem-loop and circular oligonucleotides and method of usingUS5703054 *Jul 9, 1993Dec 30, 1997Isis Pharmaceuticals, Inc.Oligonucleotide modulation of protein kinase CUS5712257May 23, 1995Jan 27, 1998Hem Research, Inc.Topically active compositions of mismatched dsRNAsUS5719271Aug 30, 1994Feb 17, 1998Isis Pharmaceuticals, Inc.Covalently cross-linked oligonucleotidesUS5731181Jun 17, 1996Mar 24, 1998Thomas Jefferson UniversityChimeric mutational vectors having non-natural nucleotidesUS5739271Jun 7, 1995Apr 14, 1998Gen-Probe IncorporatedThiocationic lipidsUS5789230Oct 7, 1994Aug 4, 1998Boehringer Ingelheim International GmbhEndosomolytically active particlesUS5801154 *Apr 8, 1997Sep 1, 1998Isis Pharmaceuticals, Inc.Antisense oligonucleotide modulation of multidrug resistance-associated proteinUS5811275Jun 5, 1995Sep 22, 1998The Regents Of The University Of CaliforniaHIV-specific ribozymesUS5811300Sep 23, 1994Sep 22, 1998Ribozyme Pharmaceuticals, Inc.TNF-α ribozymesUS5814500Oct 31, 1996Sep 29, 1998The Johns Hopkins University School Of MedicineDelivery construct for antisense nucleic acids and methods of useUS5824519Nov 8, 1995Oct 20, 1998Medical University Of South CarolinaTissue-specific and target RNA-specific ribozymesUS5837510Jun 6, 1995Nov 17, 1998Goldsmith; Mark A.Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disordersUS5854067Jan 19, 1996Dec 29, 1998Board Of Regents, The University Of Texas SystemHexokinase inhibitorsUS5864028Jun 5, 1995Jan 26, 1999Gene Shears Pty. LimitedDegradation resistant mRNA derivatives linked to TNF-α ribozymesUS5866701Jun 17, 1993Feb 2, 1999The Board Of Regents For Northern Illinois University Of DekalbHIV targeted hairpin ribozymesUS5891717Jan 19, 1996Apr 6, 1999Betagene, Inc.Methods and compositions for inhibiting hexokinaseUS5898031Jun 6, 1996Apr 27, 1999Isis Pharmaceuticals, Inc.Oligoribonucleotides for cleaving RNAUS5908779Dec 1, 1993Jun 1, 1999University Of ConnecticutTargeted RNA degradation using nuclear antisense RNAUS5939262Jun 24, 1997Aug 17, 1999Ambion, Inc.Ribonuclease resistant RNA preparation and utilizationUS5968737Nov 12, 1996Oct 19, 1999The University Of MississippiMethod of identifying inhibitors of glutathione S-transferase (GST) gene expressionUS5985620Nov 3, 1993Nov 16, 1999Gene Shears Pty. LimitedTNF-α RibozymesUS5998203 *Apr 16, 1996Dec 7, 1999Ribozyme Pharmaceuticals, Inc.Enzymatic nucleic acids containing 5'-and/or 3'-cap structuresUS6025167Jun 5, 1996Feb 15, 2000Competitive Technologies, Inc.RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methodsUS6054299Jun 17, 1997Apr 25, 2000Conrad; Charles A.Stem-loop cloning vector and methodUS6057156Dec 4, 1997May 2, 2000Robozyme Pharmaceuticals, Inc.Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptorsUS6071890Oct 19, 1995Jun 6, 2000Genzyme CorporationOrgan-specific targeting of cationic amphiphile/DNA complexes for gene therapyUS6077705May 14, 1997Jun 20, 2000Thomas Jefferson UniversityRibozyme-mediated gene replacementUS6080851Nov 16, 1993Jun 27, 2000American Home Products CorporationRibozymes with linked anchor sequencesUS6087164Oct 1, 1998Jul 11, 2000Yissum Research Development Company Of The Hebrew University Of JerusalemMethods and compositions for inducing tumor-specific cytotoxicityUS6087172Oct 31, 1997Jul 11, 2000Hisamitsu Pharmaceutical Co., Inc.Ribozymes targeted to human IL-15 mRNAUS6099823Jul 30, 1998Aug 8, 2000Millennium Pharmaceuticals, Inc.Compositions and methods for the treatment and diagnosis of cardiovascular diseaseUS6100087Mar 11, 1998Aug 8, 2000City Of HopeRibozymes targeted to human CCR5 mRNAUS6100444Feb 11, 1997Aug 8, 2000University Of Rochester Medical CenterProstate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigenUS6107094Jun 6, 1997Aug 22, 2000Isis Pharmaceuticals, Inc.Oligoribonucleotides and ribonucleases for cleaving RNAUS6127533Jan 30, 1998Oct 3, 2000Isis Pharmaceuticals, Inc.2'-O-aminooxy-modified oligonucleotidesUS6166197Mar 6, 1995Dec 26, 2000Isis Pharmaceuticals, Inc.Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutionsUS6183959Jul 8, 1998Feb 6, 2001Ribozyme Pharmaceuticals, Inc.Method for target site selection and discoveryUS6225291Apr 21, 1998May 1, 2001University Of FloridaRod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseasesUS6245560May 18, 1994Jun 12, 2001The United States Of America As Represented By The Department Of Health And Human ServicesVector with multiple target response elements affecting gene expressionUS6245748Sep 25, 1998Jun 12, 2001Georgetown UniversityInhibition of an FGF-binding protein using ribozymesUS6255071Mar 19, 1997Jul 3, 2001Cold Spring Harbor LaboratoryMammalian viral vectors and their usesUS6271358Jul 27, 1998Aug 7, 2001Isis Pharmaceuticals, Inc.RNA targeted 2′-modified oligonucleotides that are conformationally preorganizedUS6346398Jan 11, 1996Feb 12, 2002Ribozyme Pharmaceuticals, Inc.Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptorUS6355415Sep 29, 1997Mar 12, 2002Ohio UniversityCompositions and methods for the use of ribozymes to determine gene functionUS6423489May 30, 1995Jul 23, 2002Isis Pharmaceuticals, Inc.Compositions and methods for treatment of Hepatitis C virus-associated diseasesUS6482803Sep 1, 1995Nov 19, 2002Board Of Regents, The University Of Texas SystemModification of mutated P53 gene in tumors by retroviral delivery of ribozyme AUS6486299Sep 28, 1998Nov 26, 2002Curagen CorporationGenes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesityUS6506559 *Dec 18, 1998Jan 14, 2003Carnegie Institute Of WashingtonGenetic inhibition by double-stranded RNAUS6573046Oct 28, 1999Jun 3, 2003Valigen (Us), IncEukaryotic use of improved chimeric mutational vectorsUS20020086356Mar 30, 2001Jul 4, 2002Whitehead Institute For Biomedical ResearchRNA sequence-specific mediators of RNA interferenceUS20020114784Jan 4, 2002Aug 22, 2002Medical College Of Georgia Research Institute, Inc.Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNAUS20020123034Oct 12, 2001Sep 5, 2002Dan CanaaniGenetic screening methodsUS20020132346Mar 8, 2002Sep 19, 2002Jose CibelliUse of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-cultureUS20020162126May 24, 2001Oct 31, 2002David BeachMethods and compositions for RNA interferenceUS20020173478Nov 14, 2001Nov 21, 2002The Trustees Of The University Of PennsylvaniaPost-transcriptional gene silencing by RNAi in mammalian cellsUS20030027783May 17, 2002Feb 6, 2003Magdalena Zernicka-GoetzInhibiting gene expression with dsRNAUS20030108923Sep 26, 2002Jun 12, 2003Whitehead Institute For Biomedical ResearchRNA sequence-specific mediators of RNA interferenceUS20030125281May 28, 2002Jul 3, 2003David LewisCompositions and processes using siRNA, amphipathic compounds and polycationsUS20030134808Nov 5, 2001Jul 17, 2003Jesper WengelOligonucleotide analoguesUS20030143732Aug 20, 2002Jul 31, 2003Kathy FosnaughRNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNAUS20030148341Nov 5, 2002Aug 7, 2003Sin Wun CheyGene amplification and overexpression in cancerUS20030157030Nov 4, 2002Aug 21, 2003Insert Therapeutics, Inc.Methods and compositions for therapeutic use of rna interferenceUS20030176671Feb 7, 2002Sep 18, 2003The Burnham InstituteApoptosis modulator BCL-B and methods for making and using sameUS20030180756Nov 21, 2002Sep 25, 2003Yang ShiCompositions and methods for suppressing eukaryotic gene expressionUS20030190635Jul 25, 2002Oct 9, 2003Mcswiggen James A.RNA interference mediated treatment of Alzheimer's disease using short interfering RNAUS20030198627Aug 23, 2002Oct 23, 2003Gert-Jan ArtssiRNA knockout assay method and constructsUS20040001811Mar 7, 2003Jan 1, 2004Ribopharma AgCompositions and methods for inhibiting expression of anti-apoptotic genesUS20040053875Mar 6, 2003Mar 18, 2004Ribopharma AgMethod and medicament for inhibiting the expression of a given geneUS20040072779Mar 6, 2003Apr 15, 2004Ribopharma AgMethod and medicament for inhibiting the expression of a given geneUS20060258608Apr 26, 2006Nov 16, 2006Rachel MeyersRNAi modulation of RSV and therapeutic uses thereofUS20080166800Oct 31, 2007Jul 10, 2008Roland KreutzerMethod and medicament for inhibiting the expression of a given geneUS20080171862Oct 31, 2007Jul 17, 2008Roland KreutzerMethod and medicament for inhibiting the expression of a given geneUS20080182981Oct 31, 2007Jul 31, 2008Roland KreutzerMethod and medicament for inhibiting the expression of a given geneUS20080233651Oct 31, 2007Sep 25, 2008Roland KreutzerMethod and medicament for inhibiting the expression of a given geneUS20080261303Oct 31, 2007Oct 23, 2008Roland KreutzerMethod and medicament for inhibiting the expression of a given geneAU717543B2 Title not availableAU778474B2 Title not availableAU2005201044B2 Title not availableDE10066235B4Jan 29, 2000Apr 10, 2008Alnylam Europe AgTargeted inhibition of gene expression by administration of double stranded oligoribonucleotide to a cell, useful for treating humans, animals and plants against viral infectionDE10080167B4Jan 29, 2000Mar 20, 2008Alnylam Europe AgMedikament zur Hemmung der Expression eines vorgegebenen GensDE10100586C1Jan 9, 2001Apr 11, 2002Ribopharma AgInhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal basesDE19618797A1May 10, 1996Nov 13, 1997Bertling Wolf Prof DrVehikel zum Transport molekularer SubstanzDE19631919A1Aug 7, 1996Feb 12, 1998Deutsches KrebsforschAnti-Sinn-RNA mit Sekund�rstrukturDE19956568A1Nov 24, 1999Aug 17, 2000Roland KreutzerVerfahren und Medikament zur Hemmung der Expression eines vorgegebenen GensDE20023125U1Jan 29, 2000May 15, 2003Ribopharma AgMedikament zur Hemmung der Expression eines vorgegebenen GensDE69233117D1Apr 24, 1992Aug 7, 2003Genset SaIn sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungenEP1144623B1Jan 29, 2000Aug 28, 2002Ribopharma AGMethod and medicament for inhibiting the expression of a defined geneEP1214945A2Jan 29, 2000Jun 19, 2002Ribopharma AGMethod and medicament for inhibiting the expression of a defined geneEP1230375B1Nov 17, 2000Jul 6, 2005Cancer Research Technology LimitedInhibiting gene expression with dsrnaEP1550719A1Jan 29, 2000Jul 6, 2005Alnylam Europe AGMethods and medicament for inhibition the expression of a defined geneEP1550719B1Jan 29, 2000Dec 24, 2008Alnylam Europe AGDoublestranded RNA (dsRNA) for inhibition the expression of a defined geneWO1994001550A1 *Jul 2, 1993Jan 20, 1994Hybridon, Inc.Self-stabilized oligonucleotides as therapeutic agentsWO1997005266A1Jul 25, 1996Feb 13, 1997Introgene B.V.Methods and means for targeted gene deliveryWO2001018197A1Sep 7, 2000Mar 15, 2001Ramot University Authority For Applied Research & Industrial Development Ltd.Genetic screening methodsWO2001029058A1Oct 13, 2000Apr 26, 2001University Of MassachusettsRna interference pathway genes as tools for targeted genetic interferenceWO2001036646A1Nov 17, 2000May 25, 2001Cancer Research Ventures LimitedInhibiting gene expression with dsrnaWO2001042443A1Dec 7, 2000Jun 14, 2001Institut Molekulyarnoi Biologii Im. V.A.Engelgardta Rossiiskoi Akademii NaukMethod for modifying genetic characteristics of an organismWO2001048183A2Dec 22, 2000Jul 5, 2001Devgen NvImprovements relating to double-stranded rna inhibitionWO2001068836A2Mar 16, 2001Sep 20, 2001Genetica, Inc.Methods and compositions for rna interferenceWO2001070949A1Mar 16, 2001Sep 27, 2001Benitec Australia LtdGenetic silencingWO2001075164A2Mar 30, 2001Oct 11, 2001Whitehead Institute For Biomedical ResearchRna sequence-specific mediators of rna interferenceWO2001092513A1May 29, 2001Dec 6, 2001Johnson & Johnson Research Pty LimitedMETHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAiWO2002016620A2Aug 17, 2001Feb 28, 2002Axordia LimitedModulation of stem cell differentiationWO2002026780A2Sep 26, 2001Apr 4, 2002The Burnham InstitutePaad domain-containing polypeptides, encoding nucleic acids, and methods of useWO2002044321A2Nov 29, 2001Jun 6, 2002MAX-PLANCK-Gesellschaft zur F�rderung der Wissenschaften e.V.Rna interference mediating small rna moleculesWO2002055692A2Jan 9, 2002Jul 18, 2002Ribopharma AgMethod for inhibiting the expression of a target gene and medicament for treating a tumor diseaseWO2002055693A2Jan 9, 2002Jul 18, 2002Ribopharma AgMethod for inhibiting the expression of a target geneWO2002061034A2Dec 7, 2001Aug 8, 2002Invitrogen CorporationCompositions and methods for rapidly generating recombinant nucleic acid moleculesWO2002068635A2Feb 27, 2002Sep 6, 2002Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical ResearchMethods of inhibiting expression of a target gene in mammalian cellsWO2002068637A2Oct 19, 2001Sep 6, 2002Ribozyme Pharmaceuticals, Inc.Nucleic acid-based treatment of diseases or conditions related to west nile virus infectionWO2003006477A1Jul 12, 2002Jan 23, 2003University Of MassachusettsIN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCINGWO2003012052A2Jul 30, 2002Feb 13, 2003The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesSpecific inhibition of gene expression by small double stranded rnasWO2003012082A2Jul 25, 2002Feb 13, 2003Axordia LimitedMethod for modulating stem cell differentiation using stem loop rnaWO2003016572A1Aug 16, 2002Feb 27, 2003Eli Lilly And CompanyOligonucleotide therapeutics for treating hepatitis c virus infectionsWO2003033700A1Oct 11, 2002Apr 24, 2003Ribopharma AgMethod for inhibiting the replication of virusesWO2003035082A1Oct 25, 2002May 1, 2003Ribopharma AgDrug for inhibiting expression of a target geneWO2003035083A1Oct 25, 2002May 1, 2003Ribopharma AgDrug for treating a fibrotic disease through rna interfenceWO2003035868A1Oct 25, 2002May 1, 2003Ribopharma AgMedicament that increases the effectiveness of a drug that induces receptor-mediated apoptosis in tumor cellsWO2003035869A1Oct 25, 2002May 1, 2003Ribopharma AgUse of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target geneWO2003035870A1Oct 25, 2002May 1, 2003Ribopharma AgDrug for treating a carcinoma of the pancreasWO2003035876A1Oct 25, 2002May 1, 2003Ribopharma AgUse of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virusWO2003070283A2Feb 21, 2003Aug 28, 2003Klaus StrebhardtAgent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agentWO2003070750A2Feb 20, 2003Aug 28, 2003Sirna Therapeutics, IncRna interference mediated inhibition of hepatitis c virusWO2003070969A2Feb 18, 2003Aug 28, 2003Sirna Therapeutics, Inc.RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)WO2003070972A2Feb 20, 2003Aug 28, 2003Sirna Therapeutics Inc.RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)WO2003074654A2Feb 20, 2003Sep 12, 2003Sirna Therapeurics, IncRna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)WO2003080794A2Jul 26, 2002Oct 2, 2003Mirus CorporationInhibition of rna function by delivery of inhibitors to animal cellsWO2003080807A2Mar 21, 2003Oct 2, 2003President And Fellows Of Harvard CollegeCompositions and methods for suppressing eukaryotic gene expression* Cited by examinerNon-Patent CitationsReference1"InBase, The Intein Database: The Intein Registry—Inteins Sorted by Species," http://tools.neb.com/inbase/list.php (database updated on May 22, 2006).2Agami, R. "RNAi and related mechanisms and their potential use for therapy". Current Opinion in Chemical Biology, 2002, vol. 6., pp. 829-834.3Agrawal et al., "Antisense Therapeutics: is it as simple as complementary base recognition?", Molecular Medicine Today 2000, vol. 6, pp. 72-81.4Agrawal et al., 1995, 105-21, Editors: Akhtar, Saghir, Publisher CRC.5Agrawal, S., "Antisense oligonucleotides: towards clinical trials," Tibtech (1996), 14: 376-387.6Agrawal, S., et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA (1988), 85:7079-7083.7Agrawal, S., et al., "Protocols for Oligonucleotides and Analogs," Chapters 5 and 6, 1993, pp. 81-140, Humana Press, Totowa, NH.8Alfonzo et al., "The mechanism of U insertion/deletion RNA editing in kinetoplastid mitochondria," Nucleic Acid Research, 25:3751-3759, 1997.9Ambros, V., (2001), "Dicing Up RNAs", Science, 293:811-813.10Anderson, "Human Gene Therapy" Nature, 392:25-30, 1998.11Armentano et al., "Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B" Proc. Natl. Acad. Sci USA 87:614-645, 1990.12Asanuma, H. et al., (1999), "Photoregulation der Bildung und Dissoziation eines DNA-Duplexes-durch cis-trans-Isomerisierung einer Azobenzoleinheit", Angew. Chem., 111:2547-2549.13Ausubel et al., "Cationic Lipid-Mediated Transfection of Suspension Cells with DNA" Curr. Protocols Mol. Biol. Supp. 48:9.4.7-9.4.8 (1999).14Auszug aus der online-Rolle des EPA, Excerpt from the European Patent Register for EP 1147204, Database last updated on Jun. 18, 2008, 4 Pages.15Azhayeva, E. et al., (1997), "Inhibitory properties of double helix forming circular oligonucleotides", Nucl. Acids Res., 25:4954-4961.16Bahramian et al.; Molecular and Cellular Biology, vol. 19:274-283, Transcriptional and Posttranscriptional Silencing of Rodent alphal(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999.17Bahramian et al.; Molecular and Cellular Biology, vol. 19:274-283, Transcriptional and Posttranscriptional Silencing of Rodent αl(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999.18Barber et al., "Mutants of the RNA-Dependent Protein Kinase (PKR) Lacking Double-Stranded RNA Binding Domain I Can Act as Transdominant Inhibitors and Induce Malignant Transformation," Mol. Cell. Biol., 15(6):3138-3146 (1995).19Barlow et al., "Interferon synthesis in the early post-implantation mouse embryo" Differentiation 27:229-235 (1984).20Barwkar, D.A. et al.; Proc. Natl. Acad. Sci USA, vol. 95:11047-11052, Sep. 1998, Chemistry, Biochemistry.21Basbaum et al., "Focalized proteolysis: spatial and temporal regulation of extra cellular matrix degradation at the cell surface"Curr. Opin. Cell Biol. 8:731-738, 1996.22Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.23Baulcombe, D.C., et al., "Mechanisms of Pathogen-Derived Resistance to Viruses in Transgenic Plants," The Plant Cell (1996), 8: 1833-1844.24Baxevanis, A., "The Molecular Biology Database Collection: 2003 udpate," Nucleic Acids Research, 2003, pp. 1-12, vol. 31, No. 1.25Beck, "Unknotting the Complexities of Multidrug Resistance: The Involvement of DNA Topoisomerases in Drug Action and Resistance" J. Natl. Cancer Inst. 81:1683-1685, 1989.26Berkner et al., "Development of Adenovirus Vectors for the Expression of Heterologous Genes" BioTechniues 6 (7):616-629, 1998.27 *Bernstein et al. Nature vol. 409, Jan. 18, 2001.28Bhan et al., Acid Research, 1997; vol. 25; p. 3310.29Billy, et al. (2001) PNAS 98(25):14428-33.30Biotechnology Applied Biochemistry vol. 29, Part 1, Feb. 1999, which shows Braun, H., et al., "Oligonucleotide and plasmid DNA packaging into polyoma VPI virus-like particles expressed in Escherichia coli," as first published on the internet Dec. 22, 1998.31Birkedal-Hansen et al., "Matrix Metalloproteinases: A Review" Crit. Rev.Oral Biol. Med. 4:197-250, 1993.32Boese et al., "Mechanistic Insights Aid Computational Short Interfering RNA Design" Methods in Enzymology 392:73-95, 2005.33Borecky et al. (1981-82) Tex Rep Biol Med 41:575-81 Abstract Only.34Boyd, "Invasion and metastasis" Cancer Metastass Rev. 15:77-89, 1996.35Braasch et al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA" Chem. Biol. 8:1-7, 2001.36Braich et al., "Regiospecific Solic-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2', 5'-(or 2', 3'-) and 3', 5'-Phosphodiester Linkages on the Formation of Hairpin DNA" Bioconjugate Chem. 8:370-377 (1997).37Braich et al., "Regiospecific Solic-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2′, 5′-(or 2′, 3′-) and 3′, 5′-Phosphodiester Linkages on the Formation of Hairpin DNA" Bioconjugate Chem. 8:370-377 (1997).38Branch, "A good antisense molecule is hard to find" TIBS, 23:45-50, 1998.39Braun, H., et al., "Oligonucleotide and plasmid DNA packaging into polyoma VPI virus-like particles expressed in Escherichia coli," Biotechnol. Appl. Biochem, 1999, pp. 31-43.40Brennicke et al., "RNA editing," FEMS Microbiology Reviews, 23:297-316 (1999).41Brinckerhoff et al., "Matrix metalloproteinases: a tail of a frog that became a prince" Nature Reviews 3:207-214, 2002.42Bruening, "Plant Gene Silencing Regularized" Proc. Natl Acad Science 95:13349-13351, 1998.43Bucchini et al., "Pancreatic Expression of Human Insulin Gene in Transgenic Mice" PNAS USA 83:2511-1515,1986.44Bumcrot, D., et al., "RNAi therapeutics: a potential new class of pharmaceutical drugs," Nature Chemical Biology (2006), 2(12): 711-719.45Burke et al., "Appearance of Interferon Inducibility and Sensitivity during Differentiation of Murine Teratocarcinoma Cells in Vitro" Cell 13:243-248 (1978).46Burke, "Appearance of Interferon Inducibility and Sensitivity during Differentiation of Murine Teratocarcinoma cells In Vitro" Cell 13:243-248 (1978).47Byrom et al., "Inducing RNA1 with siRNA Cocktails Generated by RNase III", Ambion, Technical Library, TechNotes, vol. 10:1, Jun. 19, 2004.48Byrom et al., "Inducing RNAi with siRNA Cocktails Generated by RNase III," TechNotes 10(1), Ambion, http://www.ambion.com/techlib/tn/101/4.html (2004).49Cameron et al., "Inhibition of Gene Expression by a Short Sense Fragment" Nucleic Acids Research, 19:469-475, 1991.50Caplen et al., "dsRNA-Mediated Gene Silencing in Cultured Drosophila Cells: a Tissue Culture Model for the Analysis of RNA Interference" Gene 252:95-105, 2000.51Caplen, N.J. et al., (2001), "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", Proc. Natl. Acad. Sci. USA, 98(17):9742-9747.52Caplen, N.J., (2002), "A new approach to the inhibition of gene expression", TRENDS in Biotechnology, 20(2):49-51.53 *Caplen, NJ. RNAi as a gene therapy approach. Expert Opinion Biol. Thera. (2003). vol. 3(4):575-586. Ashley Publications Ltd.54Castelli, J. et al., (998), "The 2-5A system in viral infection and apoptosis", Biomed. Pharmacother., 52:386-390.55Chao et al., "BCL-2 Family: Regulators of Cell Death" Annu. Rev. Immunol. 16:395-419, 1998.56Check, E. "RNA to the rescue?", Nature, 2003, vol. 425, pp. 10-12.57Chen et al., "Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo" Proc. Natl Acad Sci. USA 91:3054-3057, 1994.58Chen, M., et al., "A universal plasmid library encoding all permutations of small interfering RNA," PNAS, Feb. 15, 2005, pp. 2356-2361, vol. 102, No. 7.59Chien et al., "Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo," Cancer Gene Therapy, pp. 1-8 (2004).60Childs et al., The MDR Superfamily of Genes and Its Biological Implciations Imp. Adv. Oncol. 21-36, 1994.61Chowdhury et al., "Long-Term Improvement of Hypercholesteromlemia AfterEx Vivo Gene Therapy in LDLR-Deficient Rabbits" Science 254:1802-1805, 1991.62Chu, C-Y., et al., "Potent RNAi by short RNA triggers," RNA, Report, 2008, pp. 1714-1719, vol. 14.63Cioca et al., "RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines" Cancer Gene Therapy 10:125-133, 2003.64Clemens MJ: PKR—a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 1997, 29(7):945-949.65Cobaleda, C. et al., (2000), "In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", Blood, 95(3):731-737.66Coburn et al., "siRNAs: a new wave of RNA-based therapeutics Journal of Antimicrobial Chemotherapy", 2003, vol. 51, pp. 753-756.67Cole et al., "Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line" Science258: 1650-1654, 1992.68Communication in opposition proceedings for German Patent No. 10066235.8 (Jun. 23, 2009).69Communication of Technical Board of Appeal in opposition to European Patent No. 1 144 623 (Sep. 22, 2008). (translation attached).70Cone et al., "High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range" Proc. Natl Acad Sci. USA 81:6349-6353, 1984.71Cook, "Medicinal chemistry of antisense oligonucleotides—future opportunities" Anti-Cancer Drug Design 6:585-607, 1991.72Corey, D.R., "Chemical modification: the key to clinical application of RNA interference?" The Journal of Clinical Investigation (2007), 117(12): 3615-3622.73Cornetta et al., "Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans" Human Gene Threapy2(1):5-14, 1991.74Cotten et al., "Ribozyme Mediated Destruction of RNA in vivo" EMBO J. 8:3861-3866, 1989.75Couture et al., "Anti-gene therapy: the use of ribozymes to inhibit gene function: Trends in Genetics." 12:510-515, 1996.76Couzin, "Small RNAs Make Big Splash," Science, 298:2296-2297 (2002).77Crooke et al., "Pharmacokinetic Properties of Several Novel Oligonucleotdies Analogs in Mice" J. Pharmacol. Exp. Ther. 277:923-937, 1996.78Crooke, S., et al., "Antisense Research and Applications," Chapters 16 and 18, 1993, CRC Press, Boca Raton, 21 pages.79 *Crooke, ST, Basic Principles of Antisense Therapeutics. Antisense Research and Application (1998), Chapter 1, Springer-Verlag, New York.80Current version of Curriculum Vitae of David M. Stalker, 2010, 13 pages.81Czaudema et al., "Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells," Nucleic Acids Res., 31(11):1-12 (2003).82Czaudema, Frank et al., "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells", Nucleic Acids Research, 2003, vol. 31, No. 11, 2705-2716.83Dai et al., "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo" Proc. Natl Acad. Sci. USA 89:10892-10895, 1992.84Damha, M., et al., "Chapter 5: Oligoribdonucleotides synthesis: the silyl-phosphoramidite method," Methods in Molecular Biology 20, Humana Press NJ: 81-114 (1993).85Danos et al., "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges" Proc. Natl. Acad. Sci. USA 85:6460-6464, 1998.86D'Ari, "Cycle-regulated genes and cell cycle regulation" Bioassays 23: 563-565, 2001.87Datenbank Medline bei STN: AN 1999091059 Medline; DN 99091059 zu: Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway, Abstract Only.88De Fougerolles et al., "RNA interference in vivo: toward synthetic smallinhibitory RNA-based therapeutics," Methods in Enzyme. 392:278-296 (2005).89Dean, N.M., et al., "Identification and Characterization of Second-Generation Antisense Oligonucleotides," Antisense & Nucleic Acid Drug Development (1997), 7: 229-233.90Decision by German Patent Office in opposition proceedings for DE 10080167.6 (Feb. 17, 2009), 20 pages.91Decision of Board of Appeal in Opposition for EP 114 46 23 (Mar. 29, 2009) (translation attached).92Decision of Rejection for Japan Patent Application No. 2009-002824, Mar. 9, 2010, 4 Pages.93Decision of Rejection for Japan Patent Application No. 2009-002826, Mar. 9, 2010, 4 Pages.94Decision of the Board of Appeal of May 19, 2010 in Opposition to European Patent No. EP 1214945, Jul. 20, 2010, 28 pages.95Decision of the Technical Board of Appeals for European Patent No. 1144623, Dec. 9, 2008, 50 Pages.96Decision on the revocation of European Patent No. 1214945, Mar. 31, 2009, 61 Pages.97Decision to revoke European Patent EP 10080167 of Alnylam Europe AG, Mar. 18, 2009, 26 Pages.98Decision to revoke European Patent EP 1144623 of Alnylam Europe AG, Dec. 19, 2008, 50 Pages.99Decision to revoke European Patent EP 1214945 of Alnylam Europe AG, Jan. 20, 2009, 56 Pages.100Declaration of David Keith Myers filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).101Declaration of David M. Stalker filed in opposition proceedings for Australian Patent 778474 (Nov. 4, 2008) (17 pages).102Declaration of David M. Stalker filed in opposition proceedings for Australian Patent 778474 (Nov. 4, 2008) (45 pages).103Delgado et al., "The Uses and Properties of PEG-Linked Proteins" Crit. Rev. Therap. Drug Carrier Sys. 9:249-304, 1992.104Dellweg et al., ed., R�mpp Lexikon Biotechnologie, p. 354 and p. 673 (1992) (in German).105Docherty et al., "Nutrient regulation of insulin gene expression" FASEB J. 8:20-27, 1994.106Doench, J.G. et al., (2003), "siRNAs can function as miRNAs", Genes & Development, 17:438-442.107Dolinnaya, et al., "Oligonucleotide circularization by template-directed chemical ligation" Nucleic Acids Research, 21:5403-5407, 1993.108Donz�, O. et al., (2002), "RNA interference in mammalian cells using siRNAs synthesized with T7 RNA Polymerase", Nucleic Acids Research, 30(10):e46(4pages).109Downward, J. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21ras", Proc. Natl. Acad. Sci. USA, 87:5998-6002.110Eder et al., "Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation" Leukemia 13:1383-1389, 1999.111Eglitis et al., "Gene Expression in Mice After High Efficiency Retroviral-Mediated Gene Transfer" Science 230:1395-1398, 1985.112 *Elbashir et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate.113Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods, 26:199-213 (2002).114Elbashir, et al. (2001) Nature 411:494-498.115Elbashir, S.M. et al., (2001), "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", The EMBO Journal, 20(23):6877-6888.116Elbashir, S.M. et al., (2001), "RNA interference is mediated by 21- and 22-nucleotide RNAs", Genes & Development, 15:188-200.117Eriksson et al., "Establishment and characterization of mouse stain (TLL) that spontaneously develops T-cell lymphomas/leukemia" Exp. Hematol. 27:682:688, 1999.118Examination Report for German Divisional Patent Application No. DE 10066382.6, Apr. 8, 2011, 13 pages.119Exhibit 1 of David Keith Myers Declaration filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).120Exhibit 2 of David Keith Myers Declaration filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).121Expert-Bezancon et al., "Precise localization of several covalent RNA-RNA cross-link in Escherichia coli 16S RNA" European Journal of Biochemistry, 136:267-274, 1983.122Extended European Search Report and Written Opinion, mailed Aug. 8, 2011 for European Patent Application No. EP 10011217.6, 21 Pages.123Fallert-M�ller, ed., Encyclopedia of Biochemistry, vol. J-Z, pp. 448-449 (2000) (in German).124Fan et al., "Reversal of Multidrug Resistance in Cancer", ed. Kellen, CRC, Boca Raton, FL, pp. 93-125.125Ferry et al., "Retroviral-mediated gene transfer into hepatocytes in vivo" Proc. Natl. Acad Sci. USA 88:8377-8381, 1991.126Fire et al., "RNA Interferences—gene silencing by double-stranded RNA" The Nobel Prize in Physiology or Medicine, press release, 2006.127Fire, 9/99, RNA-triggered gene silencing, Trends Genet, 15: 358-363.128Fire, A. et al., (1998), "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", Nature, 391:806-811.129Fire, A., "Gene Silencing By Double Stranded RNA," Nobel Lecture, Dec. 8, 2006, pp. 198-233.130Fire, A., et al., 1991, Production of Antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle, Development 113: 503-514.131Forstova, J. et al., "Polyoma Virus Pseudocapsids as Efficient Carriers of Heterologous DNA into Mammalian Cells," Human Gene Therapy (1995), 6: 297-306.132Fotedar et al., "Apoptosis and the cell cycle" Prog. Cell Cycle Res. 2:147-163,1996.133Gait, M., "Chapter 16: Oligoribdonucleotides," Antisense Research and Applications, CRC Press 289-302, 1993.134 *Gao et al. Nucleic Acids Research vol. 23, No. 2, 1995.135Gao et al., "Circularization of oligonucleotides by disulfide bridge formation" Nucleic Acids Research, 23:2025-2029, 1995.136Garnier, L. et al., "Incorporation of Pseudorabies Virus gD into Human Immunodeficiency Virus Type 1 Gag Particles Produced in Baculovirus-Infected Cells," Journal of Virology (1995) 69(7): 4060-4068.137Gassmann et al., "Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells" PNAS USA 92:1292-1296, 1995.138Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins", Journal of the National Cancer Institute, 93(6):463-471.139GenBank Accession No. M13994, "Human B-cell leukemia/lymphoma 2 (bc102) proto-oncogene mRNA encoding bcl-2 beta protein" Oct. 31, 1994.140GenBank Accession No. M13995, "Human B-cell leukemia/lymphoma 2 (bc102) proto-oncogene mRNA encoding bcl-2 beta protein" Oct. 31, 1994.141GenBank Accession No. U55763, "Cloning vector pEGFP-CA, complete sequence, enhanced green fluorescent protein (egfp) and neomycin phosphotransferase genes" Jun. 15, 1996.142German Opposition, filed by Pfizer Inc. on Jun. 19, 2008, in opposition to German Patent DE 10066235.8 (Lederer & Keller) 34 pages.143Gewirtz, A., et al., "Nucleic Acid Therapeutics: State of the Art and Future Prospects," Blood, Aug. 1, 1998, pp. 712-736, vol. 92, No. 3.144Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", Proc. Natl. Acad. Sci. USA, 85:5026-5030.145Gillock, E. T. et al., "Polyomavirus Major Capsid Protein VP1 is Capable of Packaging Cellular DNA When Expressed in the Baculovius System," Journal of Virology (1997),71(4): 2857-2865.146Graessman et al., "Inhibition of SV40 Gene Expression by Microinjected Small Antisense RNA and DNA Molecules" Nucleic Acids Research 19:53-59, 1991.147Graham, "Mapping Transgene Activity in Plants Using Visible Phenotypes" Australian Society for Biochemistry and Molecular Biology Incorporated and Australian Society of Plant Physiologists Incorporated, vol. 28, Abstract SYM-18-06 (1996).148Grasby, JA et al.; Biochemistry Mar. 28, 1995; 34(12);4068-76.149 *Green et al. Antisense Oligonucleotides: An evolving technology for the modulation of gene expression in human disease. J AM Coll Surg. 2000, vol. 191:93-105. American College of Surgeons.150Grierson et al., "Does Co-Suppression of Sense Genes in Transgenic Plants Involve Antisense RNA?" Trends in Biotechnology 9:122-123, 1991.151Griffey, RH et al.; J Med Chem Dec. 20, 1996; 39(26);5100-9.152Grounds of Appeal filed by Alnylam Europe AG for European Patent EP 1214945, filed Aug. 5, 2009, 21 pages.153Grounds of Appeal filed by Appellant Sanofi-Aventis Deutschland GmbH, on Oct. 26, 2010, against German Patent No. DE 10066235.8, 21 pages.154Grounds of Appeal filed by Appellant Silence Therapeutics AG, on Nov. 23, 2010, against German Patent No. DE 10066235.8, 48 pages.155Gryaznov et al., "Template controlled coupling and recombination of oligonucleotide blocks containing thiophosphoryl groups,"Nucleic Acids Res., 21(6):1403-1408 (1993).156Guang et al., "An Argonaute Transports siRNAs from the Cytoplasm to the Nucleus" Science 321:537-541, 2008.157Guo et al., "Par-1 a Gene Required for Establishing Polarity in C. elegans Embryos, Encodes a Putative Ser/Thr Kinase That is Asymmetrically Distributed" Cell 81:611-620, 1995.158Ha, I et al.; Genes Dev Dec. 1, 1996;10(23);3041-50.159Haborth et al., Identification of essential genes in cultured mammalian cells using small interfering RNAs, Journal of Cell Science 114:4557-4565, 2001.160Hamada M. et al., "Effects of RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3′-Ends of siRNAs," Antisense and Nucleic Acid Drug Development, 2002, vol. 12, pp. 301-309.161Hamilton et al.; Science, vol. 286:950-951, A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants (Oct. 29, 1999).162Hamm et al., "Incorportation of 2′-Deoxy-2′mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry" J. Org. Chem. 62:3415-3420, 1997.163Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells", Nature, 404:293-296.164Hanahan et al., "The Hallmarks of Cancer" Cell 100:57-70, 2000.165Harada et al., "Absence of the Type I IFN System in EC Cells: Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes Are Developmentally Regulated" Cell 83:303-312 (1990).166Harada et al., "Absence of the Type I IFN System in EC Cells: Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes are Developmentally Regulated," Cell 83:303-312 (1990).167Harborth, J. et al., (2001), "Identification of essential genes in cultured mammalian cells using small interfering RNAs", Journal of Cell Science, 114(24):4557-4565.168Harfe et al., "Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning" Genes & Development 12:2623-2635 (1998).169Harris et al., "The Eu-myc Transgenic Mouse A Model for High-incidence Spontaneous Lymphoma and Leukemia of Early B Cells" J. Exp. Med. 167(2)353-371, 1988.170Hedges, "The Origin and Evolution of Model Organisms," Nature Reviews, 3:838-849 (2002).171Hoke, GD et al.; Nucleic Acids Res Oct. 25, 1991; 19(20):5743-8.172Holen, T. et al., (2002), "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", Nucleic Acids Research, 30(8):1757-1766.173Horn, T et al.; Nucleic Acids Research, 1997, vol. 25, No. 23 : 4842-4849.174Hornung et al., "Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7,"Nature Medicine, 11(3):263-270 (2005).175Hsu et al., "Immunogencity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenovirus Types 4, 5, and 7Vectors in Dogs and a Chimpanzee" J. Infectious Disease 166:769-775, 1992.176Huber et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma. An innovative approach for cancer therapy" Proc. Natl Acad. Sci USA 88:8039-8043, 1991.177Hu-Lieskovan et al., "Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma" Cancer Res., 65(19):8984-8992 (2005).178Hung, C., et al., "A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells," Biochemical and Biophysical Research Communications, 2006, pp. 707-720, vol. 346.179Hunter et aL, "The characteristics of inhibition of protein synthesis by double stranded ribonucleic acid in reticulocyte lysates," J. Biol. Chem., 250(2):409-417 (1975).180Hunter et al., "Genetics: A touch of elegance with RNAi" Curr. Biol. 9:R440-R442 (1999).181Hunter, Jun. 17, 1999, A touch of elegance with RNAi, Curr Biolo, 9: R440-R442.182Hwu et al., "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced with Tumor Necrosis Factor-alpha cDNA for the Gene Therapy of Cancer in Humans" J. Immunol. 150:4104-4115, 1993.183Interlocutory Decision in opposition proceedings for European Patent No. 1144623 (Sep. 25, 2006), 72 pages.184International Preliminary Examination Report from PCT/DE00/00244.185International Search Report of International Application No. PCT/DE2000/00244, Jun. 20, 2000, 6 pages.186International Search Report of International Application No. PCT/EP2002/00151, Jan. 27, 2003, 7 pages.187Iwase, R et al.; Nucleic Acids Symp Ser 1997; (37);203-4.188Izant et al., "Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA" Science 229:345-352, 1985.189Jackson, A. L. et al., "Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity," RNA Journal, 12(7): 1179-1187 (2007).190Jacobs, B.L., and Langland, J.O., 1996, When two stands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349.191James D. Thompson, Dec. 1999, Shortcuts from gene sequence to function, Nature Biotechnology, vol. 17, pp. 1158-1159.192James et al., "The Therapeutic Potential of Ribozymes" Blood 91:371-382, 1998.193Jaschke et al., "Synthesis and analytical characterization of RNA polyethylene glycol conjugates" Nucleosides & Nucleotides, 15:1519-1529, 1996.194 *Jen et al. Suppresion of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells 2000, vol. 18: 307-319. AlphaMed Press.195Jennings et al., "Inhibition of SV40 Replicon Function by Engineered Antisense RNA Transcribed by RNA Polymerase III" EMBO Journal 6:3043-3047, 1987.196Jiang, A., et al., "In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies," Gene Therapy, 1999, pp. 1982-1987, vol. 6.197Jorgensen et al., "Silencing of Plant Genes by Homologous Transgenes" AgBiotech News and Information 4:265-273, 1992.198Judge A.D., et al., "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo," Molecular Therapy (2006), 13(3): 494-505.199Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," Nat. Biotechnol., pp. 1-6 (2005) (8 pages of supplementary content included).200Kabanov et al., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenze virus reproduction and synthesis of virus-specific proteins in MDCK cells" FEBS Lett. 259 (2):327-330,1990.201Kamio et al., "Nucleotide Sequence of an Incompatibility Region of Mini-Rts1 That Contains Five Direct Repeats" Journal of Bacteriology 155:1185-1191, 1983.202Kaufman et al., "Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor." PNAS USA, 96:11693-11695, 1999.203Kay et al., "Hepatic Gene Therapy: Persistent Expression of Human alphal-Antitrypsin in Mice after Direct Gene Delivery In Vivo" Human Gene Therapy 3:641-647, 1992.204Kelly, J. "Superagonist Trial Hit by Cytokine Storm," Muscoskeletal Report, Aug. 17, 2006, 3 Pages.205Kennerdell et al., "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Cell 95(7):1017-1026 (1998).206Kennerdell et al.; Cell, vol. 95, S. 1017-1026; "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Dec. 23, 1998.207Kim et al., "Stable Reduction of Thymidine Kinase Activity in Cells Expressing High Levels of Anti-Sense RNA" Cell 42:129-138, 1985.208Kitabwalla et al., "RNA-Interference—A New Weapon Against HIV and Beyond," N. Engl. J. Med., 347(17):1364-1367 (2002).209Klemens, et al.(1999), The 2 Å Structure of helix 6 of the human signal recognition particle RNA., Structure 7(11): 1345-1352.210Koshkin et al., "LNA (Locked Nucleic Acids) Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Biclonucleoside Monomors, Oligomerisation and Unprecendented Nucleic Acid Recognition," Tetrahedron 54:3507-3630, 1998.211Kovalchuk et al., "Burkitt Lymphoma in the Mouse" J. Exp. Med. 192:1183-1190, 2000.212Krepela, "Cysteine proteinases in tumor cell growth and apoptosis" Neoplasma 48:332-349, 2001.213Kreutzer et al (1999) Gesellschaft fur Biochemie und Molekularbiologie S169, Abstract Only.214Krieger et al., "The Flavr Savr Tomato, an Early Example of RNAi Technology" HortScience 43:962-964, 2008.215Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes" Microbiology and Molecular Biology Reviews, 62(4):1415-1434, 1998.216Lamond, A., et al., "Antisense oligonucleotides made of 2′-O-alky1RNA: their properties and applications in RNA biochemistry," FEBS Letters (1993), 325(1-2): 123-127.217Lee et al., "The C. elegans Herochronic Gene lin-4 Encodes Small RNAs with Antisense Complementary to lin-14" Cell 75:843-854 (1993).218Lee, et al.; Cell, vol. 88; S. 637-646; Mar. 7, 1997; The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA.219Letsinger et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture" PNAS USA 86:6553-6556, 1989.220Letter to the International Examining Authority from Gassner & Partner in the prosecution of PCT/DE00/00244 (WO 00/44895), 5 pages (Mar. 28, 2001) (in German).221Lewis, D.L. et al., (2002), "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice", Nature Genetics, 32:107-108.222Li et al. , Dev. Biology vol. 210, 1999, p. 238 abstract 346, Abstract Only.223Li et al., "Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells" Pharm. Res. 15(10):1540-1545, 1998.224Lin et al.; Nature, vol. 402:128-129, "Policing rogue genes" Nov. 11, 1999.225Lipardi, C. et al., (2001), "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs", Cell, 107:297-307.226Lipinski, et al. (1997) Adv. Drug Delivery Review 23:3-25.227Lipson et al., "Psoralen cross-linking of ribosomal RNA" Methods in Enzymology, 164:330-341, 1998.228List of Documents in Opposition to German Application No. DE 10066235, filed by Silence Therapeutics AG, Sanofi Aventis Deutschland GmbH, and Pfizer Inc., 4 pages.229Liu et al., "Detection of a novel ATP-dependent cross-linked protein at the 5′ splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking" Molecular Cell Biology, 18:6910-6920, 1998.230Livache et al., "Detection of HIV1 DNA in Biological Samples by an Homogenous Assay: Fluorescence Measurement of Double-Stranded RNA Synthesized from Amplified DNA" Analytical Biochemistry, 217:248-254, 1994.231Lopez-Fraga, M., et al., "RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease," Infectious Disorders Drug Targets (2008), 8:262-273.232Lowy, D.R. et al., (1993), "Function and Regulation of RAS", Annu. Rev. Biochem., 62:851-891.233Lubberts, E., et al., "Adenoviral Vector-Mediated Overexpression of IL-4 in the Knee Joint of Mice with Collagen-Induced Arthritis Prevents Cartilage Destruction," The Journal of Immunology, 1999, pp. 4546-4556.234Luo et al., "The Gene-Silencing Efficiency of SiRNA is Strongly Dependent on the Local Structure of mRNA at the Targeted Region" Biochemical and Biophysical Research Communications, vol. 318(1):303-10, 2004.235Ma MY (1993) Biochem. 32(7):1751-8.236Madhur Kumar et al., "Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes" Microbiology and Molecular Biology Reviews, vol. 62, Dec. 1998, pp. 1415-1434.237Maitra et al., "HIV-1 TAR RNA Has an Intrinsic Ability to Activate Interferon-Inducible Enzymes" Virology 204:823-827, 1994.238Maiumdar, A et al.; Nat Genet Oct. 1998; 20(2):212-4.239Malone, R.W. et al., "Cationic liposome-mediated RNA transfection," Proc. Natl. Acad. Sci. USA (1989), 86: 6077-6081.240Manche et al. Molecular and Cellular Biology 1992, vol. 12, pp. 5238-5248.241Manche, L. et al., (1992), "Interactions between Double-Stranded RNA Regulators and the Protein Kinase DAI", Molecular and Cellular Biology, 12(11):5238-5248.242Manoharan et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides" Ann. NY Acad. Sci. 660-306-309, 1992.243Manoharan et al., "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications" Bioorg. Med. Chem. Lett. 4(8):1053-1060, 1994.244Manoharan et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications" Bioorg. Med. Chem. Lett. 3(12):2765-2770, 1993.245Manoharan et al., "Lipidic Nucleic Acids" Tetrahedron 36:3651-3654, 1995.246Manoharan et al., "Oligonucleotide Conjugates Alteration of the Pharmacokinetic Properties of Antisense Agents" Nucleosides & Nucleotides 14:969-973, 1995.247Manoharan, M., "RNA interference and chemically modified small interfering RNAs," Current Opinion in Chemical Biology (2004), 8: 570-579.248Manoharan, Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery and Mechanism of Action: Antisense and Nucleic Acid Drug Development 12:103-128, 2002.249Marques et al., "A Structural Basis for Discriminating Between Self and Non-Self Double-Stranded RNAs In Mammalian Cells" Nature Biotechnology 24:559-65, 2006.250Marques et al., "Activation of the mammalian immune system by siRNAs," Nat. Biotechnol., 23(11):1399-1405 (2005).251Martinez et al., "Single stranded antisense siRNAs guide target RNA cleavage in RNAi," Cell, 110:563-574 (2002).252Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," Cell, 110:563-574 (2002).253Maru, "Molecular Biology of Chronic Myeloid Leukemia" Int. J. Hematol. 73:308-322, 2001.254Matrisian, "Cancer biology: Extracellular proteinases in malignancy" Curr. Biol. 9(20)R776-778, 1999.255McCaffrey, A.P. et al., (2002), "RNA interference in adult mice", Nature, 418:38-39.256McManus et al., "Gene Silencing in Mammals by Small Interfering RNAs," Nat. Rev. Genet., 3:737-747 (2002).257Meister, "RNA Interference in the Nucleus" Science 321:496-497, 2008.258Mendelsohn et al., "The EGF receptor family as target for cancer therapy" Oncogene 19(56):6550-6565, 2000.259Micura, "Cyclic oligoribonucleotides (RNA) by solid-phase synthesis" Chem. Eur. J. 5:207702082, 1999.260Mignatti et al., "Biology and Biochemistry of proteinases in Tumor Invasion" Physiol. Rev. 73:161-195,1993.261Milhaud et al., Journal of Interferon Research, 1991, vol. 11, 261-265.262Milligan et al., "Synthesis of Small RNAs Using T7 RNA Polymerase" Methods in Enzymology, 180:51-62, 1989.263Minks et al. Journal of Biological Chemistry 1979, vol. 254, pp. 10180-10183.264Minks, M. A. et al., The Journal of Biological Chemistry (1979), 254, (20):10180-10183.265Minutes of oral proceedings for European Patent EP 1214945, May 19, 2010, 13 pages.266Minutes of oral proceedings regarding opposition against German Patent DE 10066235.8, Feb. 5, 2010, 14 Pages.267Minutes of the Oral Proceedings held on Jan. 14, 2010 in Opposition to German Patent DE 10066235.8, issued by the German Patent and Trademark Office, 55 Pages.268Minutes of the Oral Proceedings in opposition proceedings for European Patent No. 1144623 (Jun. 22, 2006).269Mishra et al., "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery" Biochem. Biophys. Acta. 264:229-237, 1995.270Misquitta et al., "Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle fromation," PNAS USA, 96:1451-1456 (1999).271Misquitta, L. and Paterson, B.M., 1999, Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle formation, Proc. Natl. Acad. Sci. 96: 1451-1456.272Mizuno et al., "Regulation of Gene Expression by a Small RNA Transcript (micRNA) in Escherichia coli K-12)" Proc. Japan Acad. 59:335-338, 1983.273Monia, B.P. et al., "Evaluation of 2′-Modified Oligonucleotides Containing 2′-Deoxy Gaps as Antisense Inhibitors of Gene Expression," The Journal of Biological Chemistry (1993), 268(19): 14514-14522.274Montgomery M.K., et al., 1998, RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegan, Proc. Natl. Acad. Sci. 95: 15502-15507.275Montgomery, et al., Jul. 1998, Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression, TIG, vol. 14, No. 7., pp. 255-258.276Montgomery, M., and Fire, 1998, Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning, Genes and Development, 12: 2623-2635.277Morita et al., "RNAi Provides a New Tool for Functional Analyses of Mammalian Genes", Proteins, Nucleic Acids and Enzymes, vol. 47, No. 14, 2002, pp. 1939-1945, with English Abstract.278Moss et al., "The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA," Cell, 88:637-646 (1997).279Mullauer et al., "Mutations in apoptosis genes: a pathogenetic factor for human disease" Mutat. Res.488:211-231, 2001.280Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells" Curr. Topics Micro. Immunol. 158:97-129, 1992.281Nakamura et al., "How Does RNase H recognize a DNA-RNA Hybrid?" Proc. Natl. Acad. Sci. 88:11535-11539 (1991).282Nakamura et al., "How does RNAseH recognize a DNA-RNA Hybrid?" Proc. Natl. Acad. Sci. 88:11535-11539, 1991.283Napoli et al., "Introduction of a chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans" The Plant Cell 2:279-289, 1990.284Neilsen et al. (1997) Chem. Comm. 825-826.285Ngo, H., et al., 1998, Double-stranded RNA induces mRNA degradation in Trypanosoma brucei, Proc. Natl. Acad. Sci. 95: 14687-14692.286Nikiforov, et al. (1992) Nucleic Acids Research 20(6):1209-1214.287Nishi, T., et al., "High-Efficiency in Vivo Gene Transfer Using Intraarterial Plasmid DNA Injection following in Vivo Electroporation1," Cancer Research, Mar. 1, 1996, pp. 1050-1055, vol. 56.288Niu, G., et al., "Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor in Vivo1," Cancer Research, Oct. 15, 1999, pp. 5059-5063, vol. 59.289Normanno et al., "The role of EGF-Related Peptides in Tumor Growth" Front. Biosci. 6:D685-707, 2001.290Notice of Acceptance for Australian patent application No. AU 2008202208, Oct. 19, 2009, 3 pages.291Notice of opposition by Abbott Laboratories against European Patent No. 1 214 945 (Mar. 8, 2006).292Notice of Opposition by Alexandra Oppl against DE 10080167.6 (Jun. 20, 2008), 49 pages.293Notice of Opposition by AstraZeneca against European Patent No. 11 44 623 (May 28, 2003).294Notice of Opposition by Atugen AG against European Patent No. 11 44 623 (May 28, 2003).295Notice of opposition by Atugen against European Patent No. 1 214 945 (Mar. 8, 2006).296Notice of Opposition by Aventis against European Patent No. 11 44 623 (May 28, 2003).297Notice of Opposition by Dr. Martin Grund against European Patent No. 11 44 623 (May 28, 2003).298Notice of Opposition by Isis Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).299Notice of Opposition by Jenssen Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).300Notice of Opposition by Novartis against European Patent No. 11 44 623 (May 28, 2003).301Notice of Opposition by Pfizer against DE 10080167.6 (Jun. 19, 2008), 29 Pages.302Notice of opposition by Quark Biotech against European Patent No. 1 214 945 (Mar. 7, 2006).303Notice of Opposition by Sanofi Aventis against DE 10080167.6 (Jun. 16, 2008), 44 Pages. (Erroneously dated Jun. 16, 2007).304Notice of Opposition by Silence Therapeutics against DE 10080167.6 (Jun. 20, 2008), 53 pages.305Notice of opposition by Sima Therapeutics against European Patent No. 1 214 945 (Mar. 7, 2006).306Notice of Opposition by Sirna against DE 10080167.6 (Jun. 20, 2008), 76 pages.307Notice of Opposition by Sirna Therapeutics against European Patent No. 11 44 623 (May 19, 2003).308Notice of Opposition to Australian patent application No. AU 2008202208 filed by Sirna Therapeutics, Inc., filed on Jan. 29, 2010, 1 page.309Notice of Opposition to European Patent Application No. EP 05002454.6, filed by SIRNA Therapeutics, filed on Sep. 21, 2009, 42 Pages.310Notice of Opposition to European Patent EP 1550719 filed by Pfizer Limited, filed Sep. 23, 2009, 21 pages.311Notice of Opposition to European Patent EP 1550719 filed by Sanofi-Aventis Deutschland GmbH, filed Sep. 23, 2009, 46 pages.312Notice of Opposition to European Patent EP 1550719 filed by Sarah Elizabeth Rogues, filed Sep. 23, 2009, 24 pages.313Notice of Opposition to European Patent EP 1550719 filed by Silence Therapeutics AG, filed Sep. 24, 2009, 35 pages.314Notice of Opposition to German Application No. DE 100 66 235, filed by Pfizer Inc. on Jul. 9, 2008.315Notice of Opposition to German Application No. DE 10066235, filed by Sanofi Aventis Deutschland GmbH on Jul. 10, 2008, 42 pages.316Notice of Opposition to German Application No. DE 10066235, filed by Silence Therapeutics, AG on Jul. 10, 2008, 34 pages.317Notice of Reasons for Rejection for Japan Patent Application No. 2009-002824, Jun. 16, 2009, 15 Pages.318Notice of Reasons for Rejection for Japan Patent Application No. 2009-002826, Jun. 16, 2009, 15 Pages.319Notice of Reasons for Rejection, mailed on Nov. 1, 2011, Japanese Patent Application No. JP 2009-002825, 9 pages.320 *Novina, et al. The RNAi revolution. Nature (2004), vol. 430: 161-164. Nature Publishing Group.321Oates et al., "Too Much Interference: Injection of Double-Stranded RNA Has Non-Specific Effects in the Zebrafish Embryo" Developmental Biology 24:20-28, 2000.322Oberhauser et al., "Effective incorporation of 2′-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol" Nucl. Acids Res. 20:533-538, 1992.323Obika et al., "Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O, 4′-C-mehtyleneribonucleosides" Tetrahedron 39:5401-5404, 1998.324Office Action Communication by the German Patent and Trademark Office dated Apr. 11, 2011 for German Divisional Patent Application No. 10066344.3-41, 7 pages.325Office Action Communication pursuant to Article 94(3) EPC dated Jul. 8, 2011, for European Patent Application No. EP 06025389.5, 8 pages.326Office Action dated Jun. 17, 2011, for U.S. Appl. No. 10/612,179, 11 Pages.327Office Action for U.S. Appl. No. 10/382,768, Feb. 5, 2010, 12 Pages.328Office Action for U.S. Appl. No. 10/382,768, Nov. 26, 2010, 7 pages.329Office Action for U.S. Appl. No. 10/383,099, Dec. 17, 2009, 9 Pages.330Office Action for U.S. Appl. No. 10/612,179 Dec. 17, 2009, 9 Pages.331Office Action for U.S. Appl. No. 10/612,179, Oct. 20, 2010, 24 pages.332Office Action for U.S. Appl. No. 11/982,305, Feb. 11, 2011, 13 pages.333Office Action for U.S. Appl. No. 11/982,305, Sep. 3, 2010, 10 pages.334Office Action for U.S. Appl. No. 11/982,325, Mar. 18, 2011, 12 pages.335Office Action for U.S. Appl. No. 11/982,328, Oct. 6, 2010, 11 pages.336Office Action for U.S. Appl. No. 11/982,345, Mar. 18, 2011, 14 pages.337Office Action for U.S. Appl. No. 11/982,345, Oct. 6, 2010, 11 pages.338Office Action for U.S. Appl. No. 11/982,411, Oct. 6, 2010, 12 pages.339Office Action for U.S. Appl. No. 11/982,425, Feb. 11, 2011, 13 pages.340Office Action for U.S. Appl. No. 11/982,425, Sep. 3, 2010, 10 pages.341Office Action for U.S. Appl. No. 11/982,434, Mar. 18, 2011, 12 pages.342Office Action for U.S. Appl. No. 11/982,434, Oct. 6, 2010, 11 pages.343Office Action for U.S. Appl. No. 11/982,441, Mar. 18, 2011, 12 pages.344Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186339 (Appeal No. 2009-11870), 10 pages.345Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186340 (Appeal No. 2009-11715), 11 pages.346Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186341 (Appeal No. 2009-11871), 6 pages.347Opalinska et al., "Nucleic acid therapeutics: basic principles and recent applications", Nature Review 2002, vol. 1, pp. 503-514.348Ouchi et al., "Synthesis and Antitumor Activity of Poly(Ethylene Glycol)s Linked to 5-Flurouracil via Urethane or Urea Bond" Drug Design and Discovery 9:93-105, 1992.349Overview, http://arthritis-research.com/content/figures/ar1168-1.jpg, Jan. 12, 2010.350Oxford Advanced Learner's Dictionary of Current English, p. 253.351Paddison, P.J. et al., (2002), "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", Genes & Development, 16:948-958.352Pandolfi, "In vivo analysis of the molecular genetics of acute promyelocytic leukemia"Oncogene 20:5726-5735, 2001.353 *Paroo et al. Challenges for RNAi in vivo. Trends in Biotechnology (2004), vol. 22(8) 390-394. Elsevier.354Parrish et al., "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference" Molecular Cell, 6:1077-1087, 2000.355Paul et al., "Effective expression of small interfering RNA in human cells", Nature Biotechnology 2002, vol. 29, pp. 505-508.356PCT/GB00/04404 as filed (Nov. 19, 1999).357Pegram, MD et al., J. Clin Oncol Aug. 1998; 16(8):2659-71.358Pei et al., "On the Art of Identifying Effective and Specific siRNAs" Nature Methods 3: 670-676, 2006.359Perler, "InBase: the Intein Database," Nucleic Acids Res., 30(1):383-384 (2002).360Petition by Pfizer Inc. in opposition proceedings for German Patent No. 10066235.8 (May 25, 2009), 19 pages.361Petition by Sanofi-Aventis et al. in opposition proceedings for German Patent No. 10066235.8 (May 22, 2009).362Petition by Silence Therapeutics in opposition proceedings for German Patent No. 10066235.8 (May 25, 2009), 28 pages.363Petition regarding German Patent No. DE 10080167 filed by Silence Therapeutics AG, Mar. 17, 2009, 20 pages.364Petition submitted by Alnylam Europe AG against DE 10080167.6, including claims as filed and list of documents cited (Dec. 18, 2008), 80 pages.365Phillips et al., "The NZB Mouse as a Model for Chronic Lymphocyte Leukemia" Cancer Res. 52:437-443, 2000.366Phillips, M., "Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension," Hypertension, Journal of the American Heart Association, 1997, pp. 177-187, vol. 29.367 *PiIs et al. (Nucleic Acids Research 2000, vol. 28: No. 9: 1859-1863).368Pils, W. et al., "Flexible non-nucleotide linkers as loop replacements in short double helical RNAs," Nucleic Acids Research, 28(9): 1869-1963 (2000).369Pollock et al., "Mouse models of acute promyelocytic leukemia" Curr. Opin. Hematol. 8:206-211, 2001.370Polushin et al., "Synthesis of Oligonucleotides Containing 2′-Azido- and 2′-Amnio-2′-deoxyuridine Using Phosphtriester Chemistry" Tetrahedron 37: 3227-3230, 1996.371Prakash et al., "Positional effect of chemical modifications on short interference RNA activity in mammalian cells," J. Med. Chem. 48:4247-4253 (2005).372Pschyrembel Klinisches Worterbuch, 259., neu bearbeitete Auflage, Pschyrembel Clinical Dictionary 259th, Revised Edition, 2002, 1 page, with English summary.373Psychremebel Klinisches Worterbuch, 259, neu bearbeitete Auflage.374Pusch et al., "Nucleotide Sequence Homology Requirements of HIV-1 Specific Short Hairpin RNA" Nucleic Acids Research 31:6444-6449, 2003.375Randall, G. et al., (2003), "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs", PNAS, 100(1):235-240.376Ravasio, "Selective Hydrogenations Promoted by Copper Catalysts. 1. Chemoselectivity, Regioselectivity, and Stereoselectivity in the Hydrogenation of 3-Substituted Steroids" J. Org. Chem. 56:4329-4333, 1991.377Record for the Oral proceedings before the Opposition Division from European Patent Office, in opposition of European Patent No. 1214945, Mar. 21, 2009, 92 Pages.378Reed, "Mechanisms of Apoptosis" Am. J. Pathol. 157:1415-1430, 2000.379Regalado, "Turning Off Genes Sheds New Light On How They Work," The Wall Street Journal, 4 pages (Aug. 6, 2002).380Rego et al., "Analysis of the Molecular Genetics of Acute Promyelocytic Leukemia in Mouse Models" Semin. In Hemat. 38:54-70, 2001.381Reply to notice of opposition by Alnylam Europe in the opposition proceedings of European Patent No. 1214945 (Dec. 28, 2006), 81 Pages.382Reply to Office Action per article 94 (3) EPC of Jul. 8, 2011, filed on Nov. 17, 2011, European Patent Application No. EP 06025389.5, 5 pages.383Request that patent be revoked in its entirety, in Opposition against European Patent 1214945, filed with European Patent Office Opposition Division, filed by Opponent 1, SIRNA Therapeutics on Aug. 16, 2011, 49 pages.384Response to Notice of Opposition filed against German Patent No. EP 1407044, filed by Max-Plank—Gesellschaft zur Forderung der Wissenschaften e.V., Mar. 26, 2009, 4 pages.385Response to Notice of Opposition to European Patent EP 1550719 filed by Alnylam Europe AG, filed Mar. 15, 2010, 40 pages.386Response to Official Action filed for Australian Application No. 32713/00 (Oct. 19, 2004).387Response to patentee's Grounds of Appeal filed by Quark Biotech, Inc. for European Patent EP 1214945, filed Dec. 28, 2009, 12 pages.388Response to patentee's Grounds of Appeal filed by Sirna Therapeutics AG for European Patent EP 1214945, filed Dec. 23, 2009, 60 pages.389Response to Preliminary Opinion of the Board of Appeal for European Patent EP 1214945, filed by Sirna Therapeutics, Inc., filed on Apr. 16, 2010, 15 pages.390Response to Summons for oral proceedings in Opposition against EP 1214945 filed by Silence Therapeutics AG, filed on Apr. 19, 2010, 5 pages.391Response to Summons to Attend Oral proceedings issued by the German Patent and Trademark office on Dec. 9, 2009 regarding opposition against German Patent DE 10066235.8, filed by Alnylam Europe AG and Jan. 4, 2010, 36 Pages.392Response to the Submission of Opponent 1, filed by Alnylam Europe AG on Nov. 17, 2011, Opposition against European Patent EP 1550719, 17 pages.393Response to three Notices of Opposition submitted by Alnylam Europe AG in German Patent No. 100 66 235.8-41 (Feb. 4, 2009), including list of documents cited (translation enclosed).394Reynolds et al., "Rational siRNA design for RNA interference" Nature Biotechnology 22:326-330, 2004.395Robbins et al., "Sensing the danger in RNA," Nat. Med., 11(3):250-251 (2005).396Rosenfeld et al., "Adenovirus-Mediated Transfer of a Recombinant a-Antitrypsin Gene to the Lung Epithelium in Vivo" Science 252:431-434, 1991.397Rosenfeld et al., "In Vivo Transfer to the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell 68:143-155, 1992.398Rumney, S., et al., "Structural Optimization of Non-Nucleotide Loop Replacements for Duplex and Triplex DNAs," J. Am. Chem. Soc., 1995, pp. 5635-5646, vol. 117.399Saison-Behmoaras et al., "Short modified antisense oligonucleotdies directed again st Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation" EMBO J. 10:111-118, 1991.400Scheffer et al., "The drug resistance-related protein LRP is the human major vault protein" Nat. Med. 1:578-582, 1995.401Scherr et al., "Quantitative Determination of Lentiviral Vector Particle Nos. by Real-time PCR" BioTechniques 31: 520-526, 2001.402Schlingensiepen et al., Antisense—From Technology to Therapy. Blackwell Science Ltd.,1997, vol. 6.403Schwarz et al., "Asymmetry in the assembly of the RNAi complex" Cell 115:199-208, 2003.404Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," Mol. Cell, 10:537-548 (2002).405Secrist et al., Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleotides, Nucleotides and their Biological Applications, Park City, Utah, Sep. 16-20, 1992.406Sedlik, C. et al., "Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells," Proc. Natl. Acad. Sci. USA (1997) 94: 7503-7508.407Sen, G., et al., "A Brief History of RNAi: The Silence of the Genes," FASEB J., vol. 20, pp. 1293-1299, 2006.408Seow, Y., et al., "Biological Gene Delivery Vehicles: Beyond Viral Vectors," Molecular Therapy (2009), 17(5): 767-777.409Seydoux et al., "Repression of gene expression in the embryonic germ lineage of C. elegans" Nature 382: 713-716 (1996).410Shannon et al., "Modelling myeloid leukemia tumors suppressor gene inactivation in the mouse" Semin. Cancer Biol. 1:191-199, 2001.411Sharp, P.A., (2001), "RNA interference-2001", Genes & Development, 15:485-490.412Sharp, P.A., (2001), "RNA interference—2001", Genes & Development, 15:485-490.413Sharp, P.A., 1999, RNAi and double-stranded RNA. Gene and Development 13: 139-141.414Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates" Nucl. Acids Res. 18:377703783, 1990.415Shi et al., "A CBP/p300 homolog specifics multiple differentiation pathways in Caenorhabditis elegans" Genes & Development 12(7):943-955 (1998).416Shiota et al., "I want to Know the RNAi Protocol of that Animal!—Effective RNAi in Mammal Cells", Cell Engineering, vol. 22, No. 3, 2003, pp. 310-315, with English summary.417Sijen, T. et al., (2001), "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, 107:465-476.418Simons et al., "Translational Control of IS10 Transposition" Cell 34:683-691, 1983.419Sinha, "Large-scale Synthesis. Approaches to Large-scale Synthesis of Oligodeoxynucleotides and their Analogs," Antisense—From Technology to Therapy, vol. 6, Edited by Reimar Schlingensiepen et al., pp. 29-58 (1997).420Skorski et al., "Suppression of Philadelphia Leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide" Proc. Natl. Acad. Sci. USA 91:4504-4508, 1994.421Skripkin et al., "Psoralen crosslinking between human immunodeficiency virus type 1 RNA and primer tRNA3Lys," Nucleic Acids Res., 24(3):509-514 (1996).422Sledz et al., "Activation of the interferon system by short-interfering RNAs," Nat. Cell Biol., 5(9):834-839 (2003).423Sledz et al., "RNA Interference and Double-Stranded RNA Activated Pathways" Biochemical Society Transactions 32:956-956, 2004.424Soeda, E., et al., "Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids," Gene Therapy (1998), 5: 1410-1419.425Soutschek et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," Nature, 432:173-178 (2004).426Sporlein, B., et al., "Lipofectin: direct gene transfer to higher plants using cationic liposomes," Theoretical and Applied Genetics (1991), 83: 1-5.427Sproat, B., "Chapter 18: 2-O-Alkyloligoribonucleotides," Antisense Research and Applications, CRC Press, 351-362, 1993.428Sproat, B., "Chapter 6: Synthesis of 2'-O-Alkyloligoribonucleotides," Methods in Molecular Biology 20, Humana Press, NJ: 115-142, 1993.429Statement of Grounds & Particulars of Opposition filed by Sirna Therapeutics, Inc., on Aug. 23, 2011, for Australian Patent Application No. AU 778474, 9 pages.430Statement of Grounds & Particulars of Opposition to Australian patent application No. AU 2008202208 filed by Sirna Therapeutics, Inc., filed on Apr. 29, 2010, 28 pages.431Statement of Grounds and Particulars of Opposition to Australian Application No. 778474 filed by Sima Therapeutics, Inc. (Jun. 1, 2009).432Statement of Grounds and Particulars of Opposition to Australian Patent Application No. 2005201044, filed by Sirna Therapeutics (Dec. 1, 2008).433Statement of Grounds and Particulars of Opposition to Australian Patent No. 778474, filed by Sirna Therapeutics, Inc. on Jun. 9, 2005, 22 Pages.434Statutory Declaration by David Keith Myers dated Aug. 2, 2010, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 3 pages.435Statutory Declaration by David Keith Myers dated Nov. 7, 2008, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 16 pages, list of journals published before the end of 1999 which cite a journal article authored by Andrew Fire and co-workers, and published in the journal Nature on Feb. 19, 1998.436Statutory Declaration by David Keith Myers dated Nov. 7, 2008, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 3 pages, list of patent publications having an earliest claimed priority date of Nov. 24, 1999 or earlier, which cite Fire, A., et al., (1998), Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391: 806-811.437Statutory Declaration by Martin Edward O'Brien of Spruson and Ferguson in the matter of Opposition to Australian Patent No. 778474, filed by SIRNA Therapeutics, Inc. on Sep. 9, 2005.438Statutory Declaration dated Aug. 17 , 2010 by David M. Stalker with Exhibits DMS-A to DMS-C and Exhibits DMS-41 to DMS-74 thereto in respect of opposition to accepted Australian Patent Application No. 2005201044, 30 pages439Stetler-Stevenson et al., "Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis" Annu. Rev. Cell Biol. 9:541-573, 1993.440Strasser et al., "Apoptosis Signaling" Annu. Rev. Biochem. 69:217-245, 2000.441Strauss; Science, vol. 286:886; "Candidate ‘Gene Silencers’ Found" Oct. 29, 1999.442Strauss; Science, vol. 286:886; "Candidate 'Gene Silencers' Found" Oct. 29, 1999.443Stryer, L., Biochemistry, Part 1 Molecular Design of Life, Chapter 4 DNA and RNA: Molecules of Heredity, 1988, pp. 80-82.444Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008). English translation only.445Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (Oct. 30, 2007).446Submission by Alexandra Oppl against DE 10080167.6 on Mar. 4, 2009, 14 pages.447Submission by Alnylam Europe AG in opposition to DE 10080167.6 on Mar. 4, 2009, 21 pages.448Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Apr. 21, 2006), 63 pages.449Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Dec. 7, 2004), 140 pages.450Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Jun. 25, 2007), 110 pages.451Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Jun. 7, 2006) 247 pages.452Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1 144 623 (Nov. 7, 2008). (translation attached).453Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1214945 (Nov. 20, 2008), 35 Pages.454Submission by Atugen AG opposition to European Patent No. 1 144 623 (Nov. 7, 2008), pp. 1-22 only.455Submission by Pfizer against DE 10080167.6 on Feb. 27, 2009, 8 pages.456Submission by Silence Therapeutics in the opposition proceedings of DE 10080167.6 on Feb. 20, 2009, 3 pages.457Submission by Silence Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008).458Submission by Sima Therapeutics in opposition to European Patent No. 1 144 623 (Nov. 6, 2008).459Submission by Sima Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Jan. 4, 2008).460Submission by Sima Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008). English translation only.461Submission by Sirna Therapeutics against DE 10080167.6 on Mar. 4, 2009, 62 pages.462Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 11 44 623 (Apr. 20, 2006—Uexkull & Stolberg), (Nov. 20, 2008).463Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 1144623 (Apr. 20, 2006—Isenbruck, Bosl, Horschler, Wichmann, Huhn), 20 pages.464Sui, G., et al., "A DNA vector-based RNAI technology to suppress gene expression in mammalian cells," Proc. Natl. Acad. Sci. USA, Apr. 16, 2002, pp. 5515-5520, vol. 99, No. 8.465Summons to Attend Oral Hearing regarding opposition against European Patent EP 1214945, Feb. 26, 2010, 15 pages.466Summons to attend oral proceedings in the opposition proceedings of European Patent No. 1214945 (May 6, 2008), 18 pages.467Summons to attend oral proceedings pursuant to Rule 115(1) EPC issued by the European Patent Office on Nov. 25, 2011, for Opposition against European Patent No. EP 1550719, 50 pages.468Suntharalingam, G., et al., "Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412," New England Journal of Medicine (2006), 355(10): 1018-1028.469Svinarchuk et a1., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotie conjugated to lipophilic groups" Biochimie 75:49-54, 1993.470Takayama et al., "Antisense RNA" Critical Reviews in Biochemistry and Molecular Biology 25:155-184, 1991.471 *Thomson et al. Activity of hammerhead ribozymes containing non-nucleotide linkers. Nucleic Acids Research 1993, vol. 21:5600-5603. Oxford University Press.472Thomson et al., "Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications" J. Org.Chem. 61:6273-6281, 1996.473Tijsterman, M. et al., (2002), "The Genetics of RNA Silencing", Annu. Rev. Genet., 36:489-519.474Timmons et al., "Specific interference by ingested dsRNA" Nature, 395:854, 1998.475Timmons et al.; Nature, 395(6705:854); "Specific Interference by Ingested dsRNA" Oct. 29, 1998.476Tolun et al., "Direct Repeats of the F Plasmid incC Region Express F Incompatibility" Cell 24: 687-694 (1981).477Touze, A., et al., "In vitro gene transfer using human papillomavirus-like particles," Nucleic Acids Res. (1998) 26(5): 1317-1323.478Tsutsui et al., "Role of Nine Repeating Sequences of the Mini-F Genome for Expression of F-Specific Incompatibility Phenotype and Copy Number Control" Journal of Bacteriology 155:337-344, 1983.479Tuschl et al. (Dec. 1999) Genes and Dev. 13:3191-7.480U.S. Appl. No. 60/117,635, filed Jan. 28, 1999.481U.S. Appl. No. 60/117,635, Li et al. (filed Jan. 28, 1999).482U.S. Appl. No. 60/130,377, Pachuk et al. (filed Apr. 21, 1999).483U.S. Appl. No. 60/175,440, filed Jan. I I, 2000.484Uhlenbeck, "A Small Catalytic Oligoribonucleotide" Nature 325:596-600, 1987.485Uhlmann, E. et al., "Antisense Nucleotides: A New Therapeutic Principal" Chemical Reviews, American Chemical Society, Easton, US vol. 90, No. 4, Jun. 1, 1990, pp. 543-584, ISSN:0009-2665.486Van Beusechem et al., "Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells" Proc. Natl. Acad. Sci. USA 89:7640-7644, 1992.487Van Etten, "Pathogenesis and treatment of Ph leukemia: recent insights from mouse models" Curr. Opin. Hematol. 8:224-230, 2001.488Various, "Nature Insight: RNA Interference" Nature, 431:337-378, 2004.489Verma et al., "Gene therapy—promises, problems, and prospects," Nature, 389:239-242, 1997.490Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A Compartive Analysis" J. Biol. Chem. 278:7108-7118, 2003.491Voinnet, O. and Baulcombe, D. C., Nature (1997), 398:553.492Wacheck et al., "Small Interfering RNA Targeting Bcl-2 Sensitizers Malignant Melanoma" Oligonucleotides, vol. 13 (5):393-400,2003.493Wagner, "The state of the art in antisense research" Nat. Med. 1:1116-1118, 1995.494Wagner, et al., Feb. 19, 1998, Double-stranded RNA poses puzzle, Nature, 391: 744-745.495Wang et al., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs" Nucleic Acids Research, 22:2326-2333, 1994.496Wang et al., "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking," Biochem 35:6491:6499 (1996).497Wang, S., et al., "Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol," Proc. Nat. Acad. Sci., Biochemistry, Apr. 1995, pp. 3318-3322.498Wargelius, et al., 1999, Double-stranded RNA induces specific developmental defects in zebrafish embryos, Biochem Biophys Res Com., 263: 156-161.499Waterhouse et al.; PNAS, vol. 95:13959-13964, "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"Nov. 1998.500Watkins et al., "In vivo UV cross-linking of U snRNAs that participate in trypanosome trans-splicing" Genes & Development, 5:1859-1869,1991.501Wengel, "Synthesis of 3′-C and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)" Acc. Chem, Res. 32:301-310, 1999.502Wess et al., "Early days for RNAi,"BioCentury, 11(12):A1-A8 (2003).503 *Wianny et al. Nature Cell Biology Feb. 2000: 70-75.504Wianny, et al. (2000) Nature Cell Biology 2:70-75.505Wild, K. et al., (1999), "The 2 Å structure of helix 6 of the human signal recognition particle RNA", Structure, 7(11):1345-1352.506Williams et al., "Thermodynamic Comparison of the Salt Dependence of Natural RNA Hairpins and RNA Hairpins with Non-Nucleotide Spacers" Biochemistry 35:14665-14670, 1996.507Wilson et al., "Retrovirus-mediated transduction of adult hepatocytes" Proc. Natl. Acad. Sci. USA 85:3014-3018, 1998.508Wink, M., "Gene Therapy: Strategies and Vectors" Molekulare Biotechnologie, 2004, pp. 557-577, Wiley-VCH, with English summary.509Wong et al., "Modeling Philadelphia chromosome positive leukemias" Oncogene 20:5644-5659, 2001.510Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186339, 77 pages.511Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186340, 76 pages.512Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186341, 70 pages.513Written Submission by Alnylam Europe AG in Opposition proceedings for DE 100 80 167.6 (Mar. 4, 2009) (translation attached).514Xie, Y., et al., "Efficacy of Adenovirus-mediated CD/5-FC and HSV-I Thymidine Kinase/Ganciclovir Suicide Gene Therapies Concomitant with p53 Gene Therapy1," Clinical Cancer Research, Dec. 1999, pp. 4224-4232, vol. 5.515Yang, D. et al., (2000), "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos", Current Biology, 10:1191-1200.516Yokota, "Tumor progression and metastasis" Carcinogenesis 21:497-503, 2000.517Yu, J. et al., (2002), "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells", PNAS, 99(9):6047-6052.518Zamecnik, P.C., et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA (1978), 75(1): 280-284.519Zamore et al., "Evidence that siRNAs function as guides not primers in the Drosophila and human RNAi pathways," Mol. Cell, 10:537-48 (2002).520Zamore, et al. (2000) Cell 101:25-33.521Zelphati, O., et al., "Antisense oligonucleotides in solution of encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms," Nucleic Acids Research, 1994, pp. 4307-4314, vol. 22, No. 20.522Zeng et al., "RNA Interference in human cells is restricted to the cytoplasm" RNA 8:855-860, (2002).523Zeng et al., "RNA interference in human cells is restricted to the cytoplasm," RNA, 8:855-860 (2002).524Zeng et al., "The Fetal Origin of B-Precursor Leukemia in the Eu-ret Mouse" Blood 92:3529-3536, 1988.525Zhang et al. Current Pharmaceutical Biotechnology 2004, vol. 5, pp. 1-7.526 *Zhang et al. Single processing center models for human dicer and bacterial Rnase III. Cell, 2004, vol. 118, pp. 57-68.527Zhao et al., "Double-Stranded RNA Injection Produces Nonspecific Defects in Zebrafish," Dev. Biol., 229:215-223 (2001).528Zheng et al., "Activation of the protein kinase PKR by short double-stranded RNAs with single-stranded tails," RNA, 10:1934-1945 (2004).529Zheng, L., et al., "An approach to genomewide screens of expressed small interfering RNAs in mammalian cells," Proc. Natl. Acad. Sci. USA, Jan. 6, 2004, pp. 135-140, vol. 101, No. 1.530Zwieb et al., "Evidence of RNA-RNA cross-linked formation in Escherichia coli ribsomes" Nucleic Acids Research, 5:2705-2720, 1978.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8877726Oct 19, 2012Nov 4, 2014Alnylam Pharmaceuticals, Inc.Method and medicament for inhibiting the expression of a given geneUS9133454Mar 18, 2014Sep 15, 2015Alnylam Pharmaceuticals, Inc.Method and medicament for inhibiting the expression of a given geneUS20100184039 *Jul 22, 2010Life Technologies CorporationMethods and compositions relating to labeled rna molecules that reduce gene expression* Cited by examinerClassifications U.S. Classification514/44.00A, 536/24.31, 536/24.1, 536/24.5International ClassificationA61K48/00, A61K38/00, A61K31/70, C12N15/11, C12N15/09, A61K31/713, A61K35/76, A61K47/48, A61P25/28, A61K9/127, A61P35/00, A61P31/12Cooperative ClassificationC12N15/111, C12N2310/53, C12N2330/30, A61K31/713, C12N2310/14, A61K38/00, C12N2310/111, C12N15/113European ClassificationA61K31/713, C12N15/11MLegal EventsDateCodeEventDescriptionOct 27, 2003ASAssignmentOwner name: RIBOPHARMA AG, GERMANYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;REEL/FRAME:014621/0958;SIGNING DATES FROM 20030801 TO 20030825Owner name: RIBOPHARMA AG, GERMANYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;SIGNING DATES FROM 20030801 TO 20030825;REEL/FRAME:014621/0958Jun 22, 2004ASAssignmentOwner name: ALNYLAM EUROPE AG, GERMANYFree format text: CHANGE OF NAME;ASSIGNOR:RIBOPHARMA AG;REEL/FRAME:015488/0614Effective date: 20040527Aug 30, 2004ASAssignmentOwner name: RIBOPHARMA AG, GERMANYFree format text: CORRECTIVE ASSIGNMENT TO CORRECT RECEIVING PARTY ADDRESS, PREVIOUSLY RECORDED AT REEL 014621, FRAME0958;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;REEL/FRAME:015733/0897;SIGNING DATES FROM 20030801 TO 20030825Owner name: RIBOPHARMA AG, GERMANYFree format text: CORRECTIVE ASSIGNMENT TO CORRECT RECEIVING PARTY ADDRESS, PREVIOUSLY RECORDED AT REEL 014621, FRAME0958;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;SIGNING DATES FROM 20030801 TO 20030825;REEL/FRAME:015733/0897Aug 7, 2009ASAssignmentOwner name: ALNYLAM PHARMACEUTICALS, INC., MASSACHUSETTSFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALNYLAM EUROPE AG;REEL/FRAME:023070/0300Effective date: 20090805Owner name: ALNYLAM PHARMACEUTICALS, INC.,MASSACHUSETTSFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALNYLAM EUROPE AG;REEL/FRAME:023070/0300Effective date: 20090805Apr 17, 2012CCCertificate of correctionAug 21, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services